id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2009-D-0095-0015,FDA,FDA-2009-D-0095,"Clinical Pharmacology Section of Labeling for Human Prescription Drug
and Biological Products—Content and Format; Guidance for Industry;
Availability",Notice,Notice of Availability,2016-12-05T05:00:00Z,2016,12,2016-12-05T05:00:00Z,,2016-12-05T16:25:46Z,2016-29125,0,0,09000064823deeb0
FDA-2009-D-0095-0016,FDA,FDA-2009-D-0095,Clinical Pharmacology Section of Labeling for Human Prescription Drug and Biological Products — Content and Format Guidance for Industry,Other,Guidance,2016-12-05T05:00:00Z,2016,12,2016-12-05T05:00:00Z,,2024-11-12T06:16:38Z,,1,0,09000064823e0377
FDA-2009-D-0095-0002,FDA,FDA-2009-D-0095,Clinical Pharmacology Section of Labeling for Human Prescription Drug and Biological Products--Content and Format - Draft Guidance,Other,Guidance,2009-03-04T05:00:00Z,2009,3,2009-03-04T05:00:00Z,,2024-11-07T22:03:36Z,,1,0,09000064808e9a43
FDA-2009-D-0095-0001,FDA,FDA-2009-D-0095,Draft Guidance for Industry on the Clinical Pharmacology Section of Labeling for Human Prescription Drug and Biological Products--Content and Format,Notice,Notice of Availability,2009-03-03T05:00:00Z,2009,3,2009-03-03T05:00:00Z,2009-06-02T03:59:59Z,2016-11-18T14:37:51Z,E9-04372,0,0,09000064808e801c